The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus and are accessible through GEO Series accession number GSE99690 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99690>).

Introduction {#sec001}
============

The orexin system has been shown to influence several biological processes including appetite \[[@pone.0188082.ref001]--[@pone.0188082.ref003]\], wakefulness \[[@pone.0188082.ref004]--[@pone.0188082.ref010]\], reward behaviors \[[@pone.0188082.ref011]--[@pone.0188082.ref018]\], and energy metabolism \[[@pone.0188082.ref019]--[@pone.0188082.ref024]\]. This system consists of two G-protein coupled receptors (GPCRs), the OX~1~ orexin receptor (OX~1~) and the OX~2~ orexin receptor (OX~2~), and a pair of hypothalamic peptide agonists, orexin A (OxA) and orexin B (OxB) \[[@pone.0188082.ref001]\]. The broad range of biological effects of the orexin system are attributed to widespread projections of orexigenic neurons and broad expression patterns of the receptors throughout the central nervous system \[[@pone.0188082.ref025]\].

In addition to efforts demonstrating the behavioral effects of the orexin system, a number of studies have addressed the intracellular molecular signaling events that occur in response to orexin receptor activation \[[@pone.0188082.ref026]--[@pone.0188082.ref030]\]. Upon ligand binding, these receptors can couple to various G-proteins \[[@pone.0188082.ref031]--[@pone.0188082.ref033]\] and regulate diverse signaling mechanisms including calcium influx \[[@pone.0188082.ref034]--[@pone.0188082.ref037]\], adenylyl cyclase/cAMP \[[@pone.0188082.ref038],[@pone.0188082.ref039]\], PI3K \[[@pone.0188082.ref040]\], MAPK/ERK \[[@pone.0188082.ref030],[@pone.0188082.ref041],[@pone.0188082.ref042]\], and several phospholipases \[[@pone.0188082.ref043]\], as recently reviewed \[[@pone.0188082.ref044]--[@pone.0188082.ref046]\]. While these signaling studies have provided much insight, they are largely focused on the upstream, canonical GPCR signaling pathways, leaving the detailed downstream signaling cascades unclear. Furthermore, most of these signaling studies have been done in heterologous expression systems that are non-neuronal, resulting in varied responses and raising questions of applicability to orexin receptor signaling in a neural context \[[@pone.0188082.ref037],[@pone.0188082.ref047]--[@pone.0188082.ref055]\].

In this study, we report the generation a of a neuronal cell line that stably expresses OX~1~ and the transcriptional profile seen upon receptor activation, as determined by RNA-Seq. OX~1~ activation resulted in the differential regulation of a large set of genes, several of which have previously been shown to be similarly regulated by sleep deprivation (SD), *in vivo*. Additionally, the downstream role of one of the more highly regulated genes, *Sgk1*, was further characterized.

Materials and methods {#sec002}
=====================

Cell culture {#sec003}
------------

The following cell lines were acquired from ATCC: CHO-K1 (CRL-9618), Neuro-2a (CCL-131), SH-SY5Y (CRL-2266), and AR42J (CRL-1492). GT1-7 cells were a kind gift from the lab of Pamela Mellon (University of California, San Diego), while CHO cells stably expressing OX~1~ were generously provided by the lab of Patricia McDonald (The Scripps Research Institute). All cells were grown in the presence of 10% HI-FBS (Gibco) at 37°C, 5.0% CO~2~. Base media for each cell line are as follows: DMEM, high glucose (Gibco) for GT1-7 and CHO cells, Eagle\'s Minimum Essential Medium (ATCC) for Neuro-2a (N2A) and SH-SY5Y cells, and F-12K Medium (ATCC) for AR42J cells.

Analysis of mRNA transcripts by qPCR {#sec004}
------------------------------------

Cells were grown to near confluence in 60mm culture dishes. For orexin treatments, culture media was replaced with fresh, warm media containing 100nM orexin A (OxA, Tocris) and incubated for 3h at 37°C. For OX~1~ inhibition, cells were pretreated with media containing 3μM SB-334867 (Tocris) for 10 min prior to adding OxA. RNA was purified from cells with the RNeasy Plus Mini Kit (Qiagen). First strand cDNAs were synthesized with the iScript cDNA Synthesis Kit (BioRad) in a 20μl reaction using 1μg RNA. The qPCR reactions were done in triplicate on the StepOnePlus real time PCR system (Applied Biosystems) with TaqMan gene expression assays (Applied Biosystems) using the following conditions: 1μl cDNA, 1μl TaqMan probe ([S1 Table](#pone.0188082.s003){ref-type="supplementary-material"}), 10ul TaqMan Gene Expression Master Mix (Applied Biosystems), and 8ul nuclease-free water. Thermal cycling conditions were 95°C for 10m, then 40 cycles of 95°C for 15s and 60°C for 60s.

Inositol phosphate assay {#sec005}
------------------------

To demonstrate the presence of functional orexin receptors, the IP-One HTRF assay (CisBio) was used with a modified protocol. Cells were harvested with TrypLE Express (Life Technologies), washed once with Dulbecco\'s phosphate-buffered saline (Gibco, 2.67mM KCl, 1.47mM KH~2~PO~4~, 137.93mM NaCl, 8.06mM Na~2~HPO~4~-7H~2~O), resuspended in 1X Stimulation Buffer (CisBio, 10mM Hepes, 1mM CaCl~2~, 0.5mM MgCl~2~, 4.2mM KCl, 146mM NaCl, 5.5mM glucose, 50mM LiCl, pH 7.4), and plated in 7μl aliquots into a low-volume 384-well plate (white) at a concentration of 20,000 cells per well. Serial dilutions of the orexin-A peptide (OxA, Tocris) were made at 2x final concentration in 1X Stimulation Buffer and then added to the cells in a 1:1 ratio (7μl per well). After 45 minutes at 37°C, the HTRF reagents were added (3μl each) and the plate was incubated for 1h at room temperature.

For the OX~1~ inhibition assay, 4-fold serial dilutions of SB-334867 were done in DMSO, starting from 2.5mM. 7μl of each serial dilution was then added to 293μl 1X Stimulation Buffer. These dilutions were then added in a 1:1 ratio (v/v) to each well of a low-volume 384-well plate (white) already containing 20,000 GT1-7-OX~1~ cells per well in 6μl 1X Stimulation Buffer. After a 30 minute incubation at 37°C, 2μl OxA (varying concentrations in 1X Stimulation Buffer) was added to each well (final \[DMSO\] = 1%). After 45 minutes at 37°C, the HTRF reagents were added (3μl each) and the plate was incubated for 1 hour at room temperature. Data were acquired on a Tecan Infinite M1000 Pro plate reader. All experiments were done in triplicate.

Generation of GT1-7-OX~1~ stable cells {#sec006}
--------------------------------------

The gene for human OX~1~ (Genecopoeia, EX-U0062-M02) was subcloned into pCDH-CMV-MCS-EF1-copGFP (Systems Biosciences) at the XbaI and BamHI restriction sites. Lentiviral particles were generated in HEK293T cells (ATCC) by co-transfecting the pCDH-OX~1~ plasmid with the pPACKH1 HIV Lentivector Packaging Kit (Systems Biosciences) using FUGENE HD Transfection Reagent (Promega). The lentiviral particles were then concentrated with PEG-it Virus Precipitation Solution (Systems Biosciences), resuspended in 400μl DPBS + 25mM HEPES, and stored at -80°C until ready for use. For the viral transduction, GT1-7 cells were cultured in 6-well plates to 60% confluence. Various volumes of lentivirus (50, 100, 200μl) were added directly to the culture media and mixed. After 72h, reporter gene expression and cell viability were analyzed via microscopy and the cells that demonstrated the highest levels of GFP expression with minimal cell toxicity were expanded for further analysis.

RNA-Seq library construction and sequencing {#sec007}
-------------------------------------------

GT1-7-OX~1~ cells were plated in 75cm^2^ culture flasks and grown to near confluence. For cell treatments, culture media was replaced with fresh, warm media containing vehicle (H~2~O) for 8 hours, or 200nM OxA for 3 or 8 hours. RNA was isolated with TRIzol Reagent (Life Technologies) according to manufacturer's protocol, including the addition of 10μg RNase-free glycogen (ThermoFisher). The RNA samples were then treated with DNase (New England Biolabs) to remove any genomic DNA contamination and then cleaned up with the Purelink RNA Micro Kit (Invitrogen). This process was repeated twice for n = 3 per condition. The DNase-treated Total RNA (250ng) was depleted of ribosomal RNA using the TruSeq Stranded Total RNA kit (Illumina) and quality assessed on an Agilent 2100 Bioanalyzer to confirm that 18S and 28S rRNA peaks were depleted. The rRNA-depleted RNA was converted to dsDNA libraries by following the TruSeq Stranded Total RNA sample prep kit user guide. Briefly, the RNA was fragmented, converted to cDNA, and ligated with adaptors. The adaptor-ligated DNA was then PCR amplified using 11 cycles to generate the final libraries. The final libraries were size selected and purified using 1.0 x Ampure XP beads (Beckman Coulter) then validated by the Bioanalyzer and qPCR quantified using primers that recognize the Illumina adaptors. The libraries were then pooled at equimolar ratios, quantified using qPCR (quantification of only the adaptor-ligated libraries) and loaded onto the NextSeq 500 flow cell (Illumina) at 1.8pM final concentration. Demultiplexed and quality filtered raw reads (fastq) generated from the NextSeq 500 were trimmed (adaptor sequences) using Trimmomatic, version 0.35 \[[@pone.0188082.ref056]\] and aligned to the reference genome (UCSC-mm10) using STAR, version 2.5.2a \[[@pone.0188082.ref057]\]. HTSeq-count (version 0.6.0) was used to generate gene counts and differential gene expression analysis was performed using DESeq2 (version 1.10.1, R version: 3.2.3) \[[@pone.0188082.ref058]\], comparing the OxA-treated samples to those treated with vehicle. The principle component analysis was performed via the plotPCA function in DESeq2, using the regularized log-transformed values of the 500 genes that were the most variable across all samples. In order to more closely identify the relationship between each sample and every other sample, the Euclidean distance between each pair of samples was calculated using the log-transformed values of the complete data set. Complete linkage clustering was then used to generate a sample-to-sample distance heatmap, via the pheatmap package in R source. For statistical analyses, raw counts for the two conditions of interest were imported into DESeq2 and transformed using the negative binomial Wald test. Adjusted p-values were generated via the Benjamini-Hochberg procedure.

Promoter analysis {#sec008}
-----------------

Gene symbols of the differentially expressed genes identified in the RNA-Seq data were entered into the DAVID Gene ID Conversion tool (<https://david.ncifcrf.gov/>) \[[@pone.0188082.ref059],[@pone.0188082.ref060]\] under the settings "OFFICIAL_GENE_SYMBOL" (input) and "REFSEQ_MRNA" (output). From the complete set of 332 genes that were differentially regulated 2-fold or greater by OX~1~ signaling at 3 or 8h (adj. p-values \<0.05, log~2~ Fold Change (log~2~FC) \>1.0 or \< -1.0), there were 31 official gene symbols that either were not recognized by DAVID, or could not be converted into a RefSeq_mRNA ID recognized by PSCAN, and could not be included in the PSCAN analysis. The complete list of gene ID conversions, including the unrecognized gene ID's, can be found in [S2 Table](#pone.0188082.s004){ref-type="supplementary-material"}. The remaining gene ID's were entered into the PSCAN user interface (<http://159.149.160.88/pscan/>), and run with the following settings: Mus musculus (organism), -450 +50 (region), Jaspar 2016 (Descriptors).

Comparison between GT1-7-OX~1~ RNA-Seq and SD microarray meta-analysis {#sec009}
----------------------------------------------------------------------

The RNA-Seq data from this work were cross-compared to results from an SD microarray meta-analysis \[[@pone.0188082.ref061]\]. Of the 91 SD-related mouse genes presented in the Wang, et al. study, five did not have Gene ID's that correlated to our data set (*2310076G05Rik*, *3110003A17Rik*, *4932442K08Rik*, *C330006P03Rik*, and *D930028F11Rik*) and were not included in the comparison. Notably, our data set does not distinguish between the long and short isoforms of *Rbm3*, which were oppositely regulated by SD in the meta-analysis. Therefore, we also excluded *Rbm3* for this comparison.

Sgk1 inhibition assay {#sec010}
---------------------

GT1-7-OX~1~ cells were plated in 75cm^2^ culture flasks and grown to 70--90% confluence. Growth media was replaced with fresh, warm media containing 1.0μM GSK-650394 (Apexbio Technology), or DMSO vehicle. After 30 minutes at 37°C, either H~2~O vehicle or OxA was added to the media at 200nM (final). After another 3 hours of incubation at 37°C, RNA was purified from cells with the RNeasy Plus Mini Kit (Qiagen). First strand cDNAs were synthesized with the iScript cDNA Synthesis Kit (BioRad) in 400μl reactions using 20μg RNA. The qPCR reactions were done with PowerUp SYBR Green Master Mix (Applied Biosystems) and PrimeTime qPCR primer pairs (IDT, [S3 Table](#pone.0188082.s005){ref-type="supplementary-material"}) in 20μl reactions (10μl SYBR, 2μl primer pair (500nM, final), 0.5μl cDNA), in triplicate, on the StepOnePlus real time PCR system (Applied Biosystems). Cycling conditions were 50°C for 2 minutes, 95°C for 2 minutes, then 40 cycles of 95°C for 15 seconds, 50°C for 1 minute. In addition to 89 genes of interest, primer pairs targeting seven housekeeping genes were included (*Actb*, *B2m*, *Gusb*, *Polr2a*, *Ppia*, *Rplp0*, and *Tbp*). As it demonstrated the strongest stability amongst treatments, with a geNorm M value \<0.2 (as determined via qbase+ software, version 3.1), *B2m* was used as the endogenous control for data analysis. Data were analyzed by the 2^-ΔΔC^~T~ method and represented as fold-change over control samples.

Results {#sec011}
=======

Characterization of orexin receptor-expressing cell lines {#sec012}
---------------------------------------------------------

The initial goal of this study was to identify a cell line that would be a reasonable model in which to analyze OX~1~ signaling. To that end, several cell lines, originating from different species, that have been reported to express one or both of the orexin receptors, endogenously, were acquired \[[@pone.0188082.ref051],[@pone.0188082.ref062]--[@pone.0188082.ref064]\]. Each cell line was screened for the presence of OX~1~ and OX~2~ mRNA by qPCR with a set of probes designed to span various exons ([Table 1](#pone.0188082.t001){ref-type="table"}). While some amplification was observed sporadically, the high Ct values and inconsistency between probes did not clearly demonstrate the presence of orexin receptor transcripts in any of the cell lines tested. In order to look for the presence of functional orexin receptors, the IP-One HTRF assay was employed. This assay is a FRET-based immunoassay that measures accumulation of inositol monophosphate (IP1) upon activation of the phospholipase C pathway and is often used as a measure of G~q~-coupled GPCR activation. At baseline levels, the kit components (FRET donor and acceptor) are bound together, resulting in a high HTRF ratio. Upon ligand-induced GPCR activation, production of cellular IP1 is stimulated. This native, unlabeled IP1 then displaces acceptor-labeled IP1, disrupting the proximity of the donor and acceptor molecules and resulting in decreased HTRF ratios. While this assay is commonly used to quantify IP1 production (via a standard curve), we utilized it as a simple measure of receptor functionality and did not perform this quantitation. As shown in [Fig 1](#pone.0188082.g001){ref-type="fig"}, none of the cell lines tested demonstrated detectable GPCR activation in response to increasing concentrations of the OxA peptide, whereas a CHO-based cell line stably expressing OX~1~ (CHO-OX~1~) provided a robust response.

![Characterization of cell lines previously reported to express orexin receptors.\
Each cell line was assayed for the presence of functional orexin receptors via the IP-One HTRF Assay. Cells were incubated with orexin A at various concentrations for 45 min. A CHO-based cell line stably expressing OX~1~ (CHO-OX~1~) was used as a positive control. The data are presented as a percentage of the baseline HTRF ratio (A~665~/A~620~ x 10000). Data points are mean (n = 3) and error bars represent standard error of the mean (SEM).](pone.0188082.g001){#pone.0188082.g001}

10.1371/journal.pone.0188082.t001

###### Characterization of orexin receptor expression via qPCR.

![](pone.0188082.t001){#pone.0188082.t001g}

  ---------------- -------------------------- ------------------ ------------------- ---------------------
  ** **            **Cell Line **             **CHO**            **CHO-OX**~**1**~   **AR42J**
  ** **            **Species**                Chinese Hamster    Chinese Hamster     rat
  ** **            **Type**                   Ovary              Ovary               pancreatic cancer
  ** **            **Housekeeping Gene**      Human TBP          Human TBP           Euk. 18S rRNA
  ** **            **Housekeeping Gene Ct**   27.2247+/-0.0546   27.4827+/-0.0055    14.8803+/-0.0979
  **OX**~**1**~    **Probe 1 Ct**             36.5295+/-0.7601   19.4577+/-0.0338    38.8842+/-1.9327
  **Probe 2 Ct**   40.0000+/-0.0000           36.6148+/-0.4199   40.0000+/-0.0000    
  **OX**~**2**~    **Probe 1 Ct**             36.3154+/-0.106    40.0000+/-0.0000    24.6203+/-0.0351
  **Probe 2 Ct**   32.0488+/-0.0467           32.0777+/-0.036    33.1794+/-0.1724    
  ** **            **Cell Line **             **N2A**            **SHSY5Y**          **GT1-7**
  ** **            **Species**                mouse              human               mouse
  ** **            **Type**                   neuroblast         neuroblastoma       hypothalamic neuron
  ** **            **Housekeeping Gene**      Mouse GAPDH        Human TBP           Mouse GAPDH
  ** **            **Housekeeping Gene Ct**   20.9608+/-0.0221   26.4232+/-0.0538    26.9245+/-0.0194
  **OX**~**1**~    **Probe 1 Ct**             27.2944+/-0.0469   33.9322+/-0.3944    35.4889+/-0.1255
  **Probe 2 Ct**   30.5317+/-0.0467           20.8086+/-0.0078   36.6909+/-0.343     
  **OX**~**2**~    **Probe 1 Ct**             40.0000+/-0.0000   40.0000+/-0.0000    40.0000+/-0.0000
  **Probe 2 Ct**   40.0000+/-0.0000           31.997+/-0.0948    40.0000+/-0.0000    
  ---------------- -------------------------- ------------------ ------------------- ---------------------

Three cell lines (AR42J, SH-SY5Y, and GT1-7) that have been previously reported to express orexin receptors, plus two negative control cell lines (CHO, N2A) and one positive control cell line (CHO-OX~1~), were screened for the presence of OX~1~ and OX~2~ mRNA via qPCR. Average Ct values are shown +/- standard deviation (n = 1, reads done in triplicate). Undetermined Ct values were assigned a value of 40, the total number of cycles used. The probes used for each sample are listed in [S1 Table](#pone.0188082.s003){ref-type="supplementary-material"}.

Generation of GT1-7 cells stably expressing OX~1~ {#sec013}
-------------------------------------------------

In the absence of an existing cell line that expresses OX~1~ endogenously, we turned to the construction of a neuronal cell line that would express recombinant OX~1~. As the orexin receptors are known to be highly expressed in the hypothalamus \[[@pone.0188082.ref065],[@pone.0188082.ref066]\] and GT1-7 is a mouse cell line derived from hypothalamic neurons, it seemed reasonable to use this as the parental cell line. A lentiviral transduction system was used to stably incorporate human OX~1~ into GT1-7 cells. The presence of the transcript was verified by qPCR ([Fig 2A](#pone.0188082.g002){ref-type="fig"}) and the presence of functional receptor was demonstrated via IP-One HTRF assay ([Fig 2B](#pone.0188082.g002){ref-type="fig"}). The functional response to OxA in these cells was inhibited with SB-334867 \[[@pone.0188082.ref067]\], a selective inhibitor of OX~1~([Fig 2C](#pone.0188082.g002){ref-type="fig"}).

![Generation of a GT1-7-based cell line stably expressing OX~1~.\
A lentiviral transduction system was used to generate GT1-7 cells that stably express OX~1~. (A) Presence of OX~1~ mRNA in the transduced cells was verified via qPCR. Data were analyzed by the 2^-ΔΔC^~T~ method, using mouse GAPDH as the reference, and are expressed as relative quantity (RQ), normalized to the parental cell line. (B) Parental, mock-transduced, and OX~1~-transduced GT1-7 cells were tested for the presence of functional OX~1~ via the IP-One HTRF Assay. (C) An orexin receptor antagonist, SB-334867, blocked orexin signaling in GT1-7-OX~1~ cells in a concentration-dependent manner. Data points are mean (n = 3), error bars represent SEM.](pone.0188082.g002){#pone.0188082.g002}

RNA Seq analysis {#sec014}
----------------

In order to assess changes in gene expression brought about by OX~1~ signaling, GT1-7-OX~1~ cells were treated with OxA for 3 or 8 hours. RNA-Seq analysis was then used to identify transcripts regulated differentially compared to cells treated with vehicle. To evaluate the overall relationships between samples and test for batch effects, a principal component analysis was conducted (Fig A in [S1 Fig](#pone.0188082.s001){ref-type="supplementary-material"}). In addition, for a more complete analysis of how each sample compares to every other sample, a clustering analysis was performed (Fig B in [S1 Fig](#pone.0188082.s001){ref-type="supplementary-material"}). In each case, strong clustering among replicates and treatment groups was evident. Additionally, more than 3 x 10^7^ mapped reads were obtained per sample, representing approximately 90% of total reads, while only 0.4% of reads mapped to a ribosomal RNA reference, indicating minimal rRNA contamination. The data discussed in this publication have been deposited in NCBI\'s Gene Expression Omnibus \[[@pone.0188082.ref068]\] and are accessible through GEO Series accession number GSE99690 (<https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE99690>).

As an initial characterization of the recombinant model, the basal expression of known neural marker genes was analyzed. Using the average transcripts per million (TPM) values of the vehicle-treated control samples as a measure of expression level (Avg. TPM \>2.0), GT1-7-OX~1~ cells expressed a number of neuronal marker genes \[[@pone.0188082.ref069]\], but not glial marker genes, indicating a neuronal genotype ([Table 2](#pone.0188082.t002){ref-type="table"}). Of note, as GT1-7 cells were isolated from mouse hypothalamic tumor cells designed to express the SV-40 T-antigen under the control of the gonadotropin releasing hormone (GnRH) promoter sequence \[[@pone.0188082.ref070]\], we expected to see elevated levels of GnRH in these cells. As expected, these cells express GnRH at very high levels (Avg. TPM = 3924).

10.1371/journal.pone.0188082.t002

###### Expression of neural marker genes in GT1-7-OX~1~ cells.

![](pone.0188082.t002){#pone.0188082.t002g}

  Neuronal Maker Genes   Average TPM   Glial Maker Genes   Average TPM
  ---------------------- ------------- ------------------- -------------
  Clstn2                 115.0         cd68                1.9
  TH                     69.0          s100b               1.7
  ENO2                   58.0          pecam1              0.3
  DLG4                   36.8          cldn5               0.1
  Asph                   27.0          GFAP                0.1
  Vgf                    26.1          vwf                 0.0
  MAP2                   21.0          tnf                 0.0
  Napb                   10.5          ocln                0.0
  Icam5                  10.2          ptprc               0.0
  Ttc9                   9.8                               
  Ica1l                  8.9                               
  Pgm2l1                 8.8                               
  Satb2                  7.8                               
  Cxadr                  7.1                               
  Lpl                    5.2                               
  Cacna1b                4.1                               
  Camk2b                 3.7                               
  SYP                    3.3                               
  Pcsk2                  3.1                               

To quantify the basal expression levels of known neural marker genes in GT1-7-OX~1~ cells, the TPM values of the vehicle-treated samples were used. Genes were considered to be expressed if the average TPM values were 2.0 or greater.

When the GT1-7-OX~1~ cells were treated with the OxA peptide, 5118 genes were differentially regulated with statistical significance at the 3-hour time point (adj. p-values \<0.05). Of these, 294 were regulated 2-fold or greater (257 up, 37 down, log~2~FC \>1.0 or \< -1.0). From the 8-hour OxA treatment, 3683 genes were differentially regulated with statistical significance (adj. p-values \<0.05). Of these, 116 were regulated 2-fold or greater (103 up, 13 down, log~2~FC \>1.0 or \< -1.0). Heat maps were generated to indicate the 50 most differentially regulated genes at each time point ([Fig 3](#pone.0188082.g003){ref-type="fig"}), as determined by overall fold change (adj. p-values \<0.05).

![Heat maps indicating the genes most highly regulated by OX~1~ activation.\
(A) Vehicle-treated vs. 3-hour treatment with OxA. (B) Vehicle-treated vs. 8-hour treatment with OxA. The values (colors) shown are the regularized log transformations of the original count data.](pone.0188082.g003){#pone.0188082.g003}

In order to validate the changes in gene expression demonstrated by the RNA-Seq data, the experiment was repeated and a subset of genes was analyzed by qPCR. The levels of gene expression measured were consistent with the RNA-Seq data. ([Fig 4A](#pone.0188082.g004){ref-type="fig"}). In a second, smaller validation experiment, SB-334867 was used to inhibit the orexin-dependent differential expression of another subset of genes, demonstrating that OX~1~ activation was required for these changes in transcription ([Fig 4B](#pone.0188082.g004){ref-type="fig"}).

![qPCR validation of RNA-Seq data.\
(A) A subset of genes that were differentially regulated by OX~1~ signaling in the RNA-Seq experiment were chosen for qPCR verification. GT1-7-OX~1~ cells were treated with 100nM OxA for 3 hours. The fold-change from the RNA-Seq data is included as a reference to demonstrate similarity of effects. (B) An OX~1~-specific antagonist inhibits OxA-dependent changes in transcription. GT1-7-OX~1~ cells were treated with 20μM SB-334867 for 10 minutes prior to addition of 100nM OxA for 3 hours. RNA was purified from each sample and analyzed via qPCR. Mean fold change is presented (n = 1, reads done in triplicate) with error bars representing SEM.](pone.0188082.g004){#pone.0188082.g004}

The results were also compared to a microarray study of OX~1~-expressing HEK293 cells published previously \[[@pone.0188082.ref071]\]. Of the genes that were up-regulated 2-fold or greater by OX~1~ activation in HEK293 cells, 346 had gene symbols that were present in the GT1-7-OX~1~ RNA-Seq data. Of these, only 24 (6.9%) were similarly up-regulated in GTI-7-OX~1~ cells (2-fold or greater at 3 or 8h, adj. p \<0.05). Of the genes that were down-regulated 2-fold or greater by OX~1~ activation in HEK293 cells, 370 had gene symbols that were present in the GT1-7-OX~1~ RNA-Seq data, with only 1 (0.3%) that was similarly down-regulated (2-fold or greater at 3 or 8h, adj. p \<0.05). Conversely, 5 of the 370 (1.4%) down-regulated genes were actually up-regulated 2-fold or greater at either 3 or 8h in GT1-7-OX~1~ cells. So, while some similarities were observed, the data were poorly replicated in the two systems, highlighting the importance of using an appropriate model for studying signal transduction, *in vitro*. Nevertheless, we did identify a set of genes comparably regulated by OX~1~ in both HEK293 and GT1-7 cells, strongly supporting a role for these genes in OX~1~ signal transduction ([S4 Table](#pone.0188082.s006){ref-type="supplementary-material"}).

Transcription factors regulated by OX~1~ signaling {#sec015}
--------------------------------------------------

GPCR-mediated signaling usually results in the activation or suppression of transcription factors, which then drive downstream changes in global gene expression. The data were thus searched for OX~1~-regulated genes known to encode transcription factors. Several families of related transcription factors, mostly immediate early genes, were highly regulated by orexin. These include the early growth response genes (*Egr1*, *Egr2*, *Egr3*), AP-1 (*Fos*, *Fosb*, *Junb*, *Fosl2*), high mobility group superfamily A (*Hmga1*, *Hmga2*), the Nr4a family of nuclear hormone receptors (*Nr4a1*, *Nr4a3*), the Id family of transcriptional repressors (*Id1*, *Id2*, *Id3*, *Id4*), various Kruppel-like factors and related proteins (*Klf4*, *Klf5*, *Klf6*, *Klf9*, *Klf10*, *Klf11*, *Klf13*, *Klf16*, *Glis1*, *Glis2*, *Zbtb16*), and the Runx family (*Runx1*, *Runx2*, *Runx1t1*) ([Table 3](#pone.0188082.t003){ref-type="table"}).

10.1371/journal.pone.0188082.t003

###### Partial list of transcription factors regulated by OxA in GT1-7-OX~1~ cells.

![](pone.0188082.t003){#pone.0188082.t003g}

  Gene ID   3h Log2 FC   3h Adj p-value   8h Log2 FC   8h Adj p-value
  --------- ------------ ---------------- ------------ ----------------
  Egr1      1.63         4.15E-70         0.77         7.45E-15
  Egr2      2.14         1.48E-42         1.13         1.32E-11
  Egr3      2.12         6.03E-25         0.35         2.29E-01
  Egr4      0.76         1.28E-03         0.37         NA
  Fos       1.25         3.11E-14         0.69         1.19E-04
  Fosb      3.01         1.26E-92         0.96         9.48E-09
  Fosl2     1.50         5.66E-130        0.78         1.62E-34
  Junb      1.82         3.99E-94         0.68         1.07E-12
  Glis1     1.58         1.69E-17         0.05         8.95E-01
  Glis2     0.60         5.96E-19         0.13         1.52E-01
  Hmga1     1.75         5.81E-37         1.63         6.45E-32
  Hmga2     2.11         2.28E-24         2.20         2.77E-26
  Id1       1.01         3.29E-11         0.29         1.34E-01
  Id2       0.68         1.36E-12         -0.28        1.28E-02
  Id3       1.28         4.13E-33         0.11         5.08E-01
  Id4       1.23         7.93E-11         0.30         2.38E-01
  Klf4      1.06         2.96E-18         0.20         2.28E-01
  Klf5      0.95         1.53E-07         0.47         2.48E-02
  Klf6      1.00         2.01E-39         0.60         7.32E-14
  Klf9      0.81         2.34E-44         -0.01        9.60E-01
  Klf10     1.57         3.67E-70         0.53         5.29E-08
  Klf11     -0.70        5.11E-17         -0.29        1.24E-03
  Klf13     0.55         2.23E-21         0.17         1.13E-02
  Klf16     0.95         8.55E-18         0.36         5.55E-03
  Myc       2.21         1.60E-98         1.78         1.74E-62
  Nr4a1     2.70         5.99E-71         1.49         2.45E-20
  Nr4a2     -0.10        7.88E-01         -0.04        9.29E-01
  Nr4a3     1.57         1.69E-12         0.26         4.28E-01
  Runx1     2.57         6.96E-246        1.95         2.93E-138
  Runx1t1   -1.13        1.17E-11         -0.62        3.23E-04
  Runx2     1.79         3.17E-95         0.37         3.52E-04

In order to identify the transcription factors likely responsible for driving the more downstream changes in gene expression, we performed an *in silico* analysis with PSCAN, an automated program that examines the promoter regions of regulated genes in order to identify common transcription factor binding sites \[[@pone.0188082.ref072]\]. The PSCAN analysis identified several putative transcription factors but, when combined with the expression data, strongly suggested a role for two distinct families of transcription factors in the regulation of downstream genes, the early growth response (EGR) proteins and Kruppel-like factors (KLF), in addition to the Myc transcription factor ([Table 4](#pone.0188082.t004){ref-type="table"}). Of note, the EGR genes are heavily associated with neural plasticity and memory \[[@pone.0188082.ref073]\] as well as enhanced long-term potentiation that impacts relapse in drug-related reward behaviors \[[@pone.0188082.ref074],[@pone.0188082.ref075]\], processes in which orexin signaling is known to be involved \[[@pone.0188082.ref012],[@pone.0188082.ref076]--[@pone.0188082.ref078]\].

10.1371/journal.pone.0188082.t004

###### A partial set of transcription factors identified by PSCAN analysis of genes differentially regulated by OX~1~ signaling.

![](pone.0188082.t004){#pone.0188082.t004g}

  PSCAN Results from 3h OX~1~-Regulated Transcripts   PSCAN Results from 8h OX~1~-Regulated Transcripts                                                                                                                 
  --------------------------------------------------- --------------------------------------------------- -------- ---------- ----- ---------- ---------- ------------- ---------- -------- ---------- ----- ---------- ----------
  **EGR1**                                            MA0162.2                                            9.6026   2.84E-22   265   **1.63**   0.77       **EGR1**      MA0162.2   4.0123   2.94E-05   106   **1.63**   0.77
  SP2                                                 MA0516.1                                            8.6975   1.35E-18   265   0.18       -0.13      Myog          MA0500.1   3.9488   3.81E-05   106   0.00       0.07
  SP1                                                 MA0079.3                                            8.3484   2.91E-17   265   0.25       0.05       E2F3          MA0469.1   3.8741   5.20E-05   106   0.52       0.24
  SP1                                                 MA0079.2                                            8.2675   5.68E-17   265   0.25       0.05       Tcf12         MA0521.1   3.7984   7.08E-05   106   0.07       0.00
  **EGR3**                                            MA0732.1                                            7.9222   8.97E-16   265   **2.12**   0.35       E2F4          MA0470.1   3.7032   1.04E-04   106   0.43       0.42
  E2F3                                                MA0469.1                                            7.8067   2.35E-15   265   0.52       0.24       Ascl2         MA0816.1   3.6859   1.11E-04   106   0.02       -0.03
  E2F1                                                MA0024.2                                            7.7749   2.98E-15   265   0.00       -0.04      E2F6          MA0471.1   3.5883   1.62E-04   106   0.34       0.19
  **EGR2**                                            MA0472.1                                            7.6289   9.46E-15   265   **2.14**   **1.13**   E2F1          MA0024.2   3.4454   2.79E-04   106   0.00       -0.04
  E2F4                                                MA0470.1                                            7.5845   1.34E-14   265   0.43       0.42       Tcf3          MA0522.1   3.3927   3.38E-04   106   -0.08      0.00
  EGR4                                                MA0733.1                                            7.3161   1.04E-13   265   0.76       0.37       **EGR2**      MA0472.1   3.2724   5.23E-04   106   **2.14**   **1.13**
  Tcfl5                                               MA0632.1                                            7.2269   2.01E-13   265   -0.01      0.06       Tcfl5         MA0632.1   3.2113   6.49E-04   106   -0.01      0.06
  **Egr1**                                            MA0162.1                                            6.9829   1.17E-12   265   **1.63**   0.77       SP1           MA0079.2   3.2068   6.60E-04   106   0.25       0.05
  KLF16                                               MA0741.1                                            6.8773   2.61E-12   265   0.95       0.36       MZF1          MA0056.1   3.1333   8.54E-04   106   -0.36      -0.13
  TFAP2A                                              MA0003.1                                            6.8724   2.78E-12   265   0.04       0.16       KLF16         MA0741.1   3.1222   8.86E-04   106   0.95       0.36
  GLIS2                                               MA0736.1                                            6.7071   8.43E-12   265   0.60       0.13       SP1           MA0079.3   3.1137   9.11E-04   106   0.25       0.05
  KLF5                                                MA0599.1                                            6.6776   1.07E-11   265   0.95       0.47       SP3           MA0746.1   3.0765   1.03E-03   106   0.12       0.06
  E2F6                                                MA0471.1                                            6.4745   3.96E-11   265   0.34       0.19       SP2           MA0516.1   2.9850   1.40E-03   106   0.18       -0.13
  **EGR2**                                            MA0472.2                                            6.4703   4.10E-11   265   **2.14**   **1.13**   Mafb          MA0117.1   2.9324   1.65E-03   106   0.28       -0.24
  TFAP2A                                              MA0810.1                                            6.4591   4.60E-11   265   0.04       0.16       GLIS2         MA0736.1   2.8684   2.03E-03   106   0.60       0.13
  SP4                                                 MA0685.1                                            6.4064   6.39E-11   265   -0.09      0.01       TBP           MA0108.2   2.8372   2.24E-03   106   0.08       0.12
  SP3                                                 MA0746.1                                            6.3527   9.30E-11   265   0.12       0.06       TBP           MA0108.1   2.7867   2.62E-03   106   0.08       0.12
  HINFP                                               MA0131.2                                            6.3166   1.14E-10   265   0.09       -0.03      NHLH1         MA0048.2   2.7563   2.88E-03   106   -0.04      -0.04
  TFAP2A                                              MA0003.3                                            5.8567   2.14E-09   265   0.04       0.16       SREBF2        MA0596.1   2.7123   3.29E-03   106   0.75       0.21
  ZBTB33                                              MA0527.1                                            5.8357   2.32E-09   265   0.17       0.23       KLF5          MA0599.1   2.6803   3.64E-03   106   0.95       0.47
  SP8                                                 MA0747.1                                            5.8083   2.80E-09   265   0.02       -0.13      Arnt          MA0006.1   2.5469   5.35E-03   106   -0.23      -0.12
  PLAG1                                               MA0163.1                                            5.7457   4.10E-09   265   -0.11      -0.06      **EGR3**      MA0732.1   2.5277   5.67E-03   106   **2.12**   0.35
  **Hes1**                                            MA1099.1                                            5.6521   6.99E-09   265   **1.95**   0.34       MZF1          MA0057.1   2.4225   7.63E-03   106   -0.36      -0.13
  TFAP2C                                              MA0814.1                                            5.5411   1.37E-08   265   0.09       -0.03      **EGR2**      MA0472.2   2.4220   7.63E-03   106   **2.14**   **1.13**
  **Klf4**                                            MA0039.2                                            5.3886   3.23E-08   265   **1.06**   0.20       Gmeb1         MA0615.1   2.4089   7.90E-03   106   -0.04      -0.04
  TFAP2A                                              MA0872.1                                            5.3834   3.26E-08   265   0.04       0.16       EGR4          MA0733.1   2.4006   8.09E-03   106   0.76       0.37
  Mycn                                                MA0104.2                                            5.2427   6.93E-08   265   0.31       0.41       CTCF          MA0139.1   2.3520   9.23E-03   106   0.02       0.02
  INSM1                                               MA0155.1                                            5.2409   7.15E-08   265   0.32       -0.37      NHLH1         MA0048.1   2.3479   9.34E-03   106   -0.04      -0.04
  SP1                                                 MA0079.1                                            5.2060   8.88E-08   265   0.25       0.05       MSC           MA0665.1   2.3283   9.81E-03   106   0.03       0.00
  TFAP2C                                              MA0815.1                                            5.2006   8.92E-08   265   0.09       -0.03      **Hes1**      MA1099.1   2.3026   1.05E-02   106   **1.95**   0.34
  CTCF                                                MA0139.1                                            5.1714   1.03E-07   265   0.02       0.02       NR2C2         MA0504.1   2.2793   1.12E-02   106   -0.03      -0.07
  TFAP2C                                              MA0524.2                                            5.1544   1.14E-07   265   0.09       -0.03      INSM1         MA0155.1   2.2741   1.14E-02   106   0.32       -0.37
  MZF1                                                MA0056.1                                            5.0663   1.90E-07   265   -0.36      -0.13      TFAP2A        MA0003.1   2.2472   1.22E-02   106   0.04       0.16
  NFKB1                                               MA0105.2                                            4.7060   1.15E-06   265   0.28       0.15       NFKB1         MA0105.2   2.2462   1.22E-02   106   0.28       0.15
  Gmeb1                                               MA0615.1                                            4.6534   1.47E-06   265   -0.04      -0.04      **Klf4**      MA0039.2   2.2182   1.32E-02   106   **1.06**   0.20
  HEY1                                                MA0823.1                                            4.5599   2.35E-06   265   0.51       -0.19      SP8           MA0747.1   2.1886   1.42E-02   106   0.02       -0.13
  ZBTB7A                                              MA0750.1                                            4.5509   2.47E-06   265   0.27       0.15       SREBF1        MA0595.1   2.1807   1.45E-02   106   -0.09      0.09
  **Myc**                                             MA0147.1                                            4.4119   4.64E-06   265   **2.21**   **1.78**   PAX5          MA0014.2   2.1370   1.62E-02   106   0.00       0.03
  Zfx                                                 MA0146.2                                            4.3194   7.35E-06   265   0.22       0.05       Egr1          MA0162.1   2.0647   1.93E-02   106   **1.63**   0.77
  NRF1                                                MA0506.1                                            4.3138   7.58E-06   265   0.06       0.05       ARNT          MA0259.1   2.0407   2.05E-02   106   -0.23      -0.12
  Zfx                                                 MA0146.1                                            4.3072   7.76E-06   265   0.22       0.05       TFAP2A        MA0003.3   2.0303   2.10E-02   106   0.04       0.16
  ZBTB7B                                              MA0694.1                                            4.1942   1.27E-05   265   -0.10      -0.05      TFAP2C        MA0814.1   1.8857   2.95E-02   106   0.09       -0.03
  ZBTB7C                                              MA0695.1                                            4.1463   1.58E-05   265   0.15       0.04       SP4           MA0685.1   1.8691   3.06E-02   106   -0.09      0.01
  Pax5                                                MA0014.1                                            4.1160   1.78E-05   265   0.00       0.03       **BHLHE40**   MA0464.2   1.8338   3.31E-02   106   **1.27**   0.51
  Arnt                                                MA0006.1                                            4.0922   1.97E-05   265   -0.23      -0.12      Pax2          MA0067.1   1.8106   3.48E-02   106   0.00       0.03
  **GLIS1**                                           MA0735.1                                            4.0484   2.40E-05   265   **1.58**   0.05       USF1          MA0093.1   1.7638   3.86E-02   106   -0.37      -0.17

The PSCAN results implicate several transcription factors that could be driving OX~1~-dependent changes in gene expression, a number of which were highly regulated by OX~1~ activation. Taken together, the promoter analysis and the expression data strongly suggest roles for the Myc transcription factor, as well as the early growth response (EGR) and Kruppel-like factor (KLF) families, in OX~1~ signaling. Transcription factors that were differentially regulated approximately 2-fold or greater are highlighted in bold.

Sleep deprivation-related genes {#sec016}
-------------------------------

To assess the physiological relevance of the data presented above, we searched the literature to compare our results with those from animal studies focused on orexin-related behaviors. Interestingly, there are striking similarities between our data set and those from an SD computational meta-analysis aimed at identifying highly conserved SD-related genes \[[@pone.0188082.ref061]\]. In this study, the authors combined and analyzed data from all available SD microarray studies spanning four species (mouse, rat, sparrow, and fruit fly). They found that SD resulted in a highly conserved (across at least 3 species) induction of *Egr1*, *Nr4a1*, and *Arc*, all of which were induced strongly by OxA in GT1-7-OX~1~ cells. Furthermore, the authors reported a set of 91 mouse genes that were differentially regulated during short-term SD (zeitgeber time 0-6h). Of the 90 SD-related genes that could be cross-referenced to our data (see [Materials and Methods](#sec002){ref-type="sec"}), 45.6% (41/90) were differentially regulated in response to 3h OX~1~ signaling at statistically significant levels (adj. p-value \<0.05, [Table 5](#pone.0188082.t005){ref-type="table"}). Additionally, 33.3% of these genes (30/90) were regulated in the same fashion (up or down) in both studies. These genes notably included *Egr1*, *Egr2*, *Egr3*, *Nr4a1*, *Nr4a3*, *Arc*, and *Sgk1*. Since it is known that SD results in elevated levels of OxA in the locus coeruleus and hypothalamus \[[@pone.0188082.ref079]\], increased hypothalamic OxA immunoreactivity \[[@pone.0188082.ref080],[@pone.0188082.ref081]\], and increased expression of c-fos in orexinergic neurons \[[@pone.0188082.ref082]\], these parallels between the data presented here and gene regulation in SD suggest strongly that the events occurring in OX~1~-expressing GT1-7 cells are of significant physiological relevance.

10.1371/journal.pone.0188082.t005

###### Genes regulated by both sleep deprivation and OX~1~ signaling.

![](pone.0188082.t005){#pone.0188082.t005g}

  ProbeID         GeneSymbol      Wang log2 FC   3h Log2 FC   8h Log2 FC   3h adj-p    8h adj-p
  --------------- --------------- -------------- ------------ ------------ ----------- -----------
  1416041_at      SGK1            1.09           3.24         2.12         0.00E+00    1.76E-163
  1418687_at      ARC             0.97           2.37         0.65         5.79E-71    1.25E-05
  1437247_at      FOSL2           0.87           1.50         0.78         5.66E-130   1.62E-34
  1424638_at      CDKN1A          0.79           0.95         0.64         3.00E-31    4.82E-14
  1427683_at      EGR2            0.79           2.14         1.13         1.48E-42    1.32E-11
  1425671_at      HOMER1          0.74           1.04         0.47         9.93E-41    2.57E-08
  1416064_a\_at   HSPA5           0.74           0.36         0.09         8.77E-15    1.52E-01
  1416953_at      CTGF            0.70           0.47         0.21         4.35E-02    NA
  1457472_at      GIGYF2          0.69           -0.21        0.05         3.16E-02    6.97E-01
  1428112_at      MANF            0.67           0.22         0.08         3.19E-03    4.06E-01
  1438796_at      NR4A3           0.66           1.57         0.26         1.69E-12    4.28E-01
  1419874_x\_at   ZBTB16          0.65           -1.01        -0.48        1.86E-18    4.21E-05
  1428834_at      DUSP4           0.64           1.69         1.16         3.44E-14    7.95E-07
  1417394_at      KLF4            0.64           1.06         0.20         2.96E-18    2.28E-01
  1454725_at      TRA2A           0.62           0.28         0.13         1.44E-02    3.32E-01
  1448352_at      LUZP1           0.61           0.45         0.22         1.25E-19    6.05E-05
  1436329_at      EGR3            0.60           2.12         0.35         6.03E-25    2.29E-01
  1416505_at      NR4A1           0.58           2.70         1.49         5.99E-71    2.45E-20
  1417677_at      OPN3            0.58           0.44         0.31         3.04E-02    1.79E-01
  1438201_at      PDP1            0.57           0.76         0.89         2.10E-15    6.32E-21
  1423796_at      SFPQ            0.57           0.32         0.16         4.12E-06    4.88E-02
  1417602_at      PER2            0.56           0.84         0.25         1.28E-09    1.64E-01
  1439442_x\_at   YARS2           0.55           0.32         0.35         4.93E-04    1.03E-04
  1434595_at      TRIM9           0.52           1.00         0.18         5.76E-27    1.65E-01
  1417065_at      EGR1            0.51           1.63         0.77         4.15E-70    7.45E-15
  1438724_at      OSBPL3          0.51           0.21         0.43         4.56E-03    7.96E-11
  1437868_at      FAM46A          0.50           0.39         0.33         4.49E-02    1.09E-01
  1460672_at      2410002F23Rik   -0.51          0.42         0.35         5.36E-07    4.89E-05
  1452661_at      TFRC            -0.51          0.63         0.43         1.31E-07    7.56E-04
  1439503_at      ZFP28           -0.51          -0.34        -0.06        7.17E-03    7.34E-01
  1422185_a\_at   cyb5r3          -0.53          0.12         0.10         4.67E-02    1.55E-01
  1426378_at      EIF4B           -0.53          0.30         0.27         4.74E-10    2.50E-08
  1451566_at      Zfp810          -0.53          -0.61        -0.35        7.29E-05    3.68E-02
  1421821_at      LDLR            -0.54          1.78         1.18         1.22E-186   6.26E-80
  1421033_a\_at   TCERG1          -0.54          0.38         0.19         1.03E-07    2.12E-02
  1455017_a\_at   ZMYM3           -0.54          -0.64        -0.49        5.61E-25    7.85E-15
  1428630_x\_at   HAGHL           -0.64          -0.38        -0.41        8.34E-03    4.65E-03
  1429239_a\_at   STARD4          -0.67          0.73         0.10         7.16E-12    5.61E-01
  1449039_a\_at   HNRNPDL         -0.73          0.28         0.15         3.06E-05    5.77E-02
  1418174_at      DBP             -0.78          -0.86        -0.72        6.65E-06    1.98E-04
  1434817_s\_at   RPRD2           -0.78          0.14         0.09         3.72E-02    2.44E-01

A cross-comparison of genes identified in a sleep deprivation microarray meta-analysis with genes regulated by OX~1~ in GT1-7-OX~1~ cells indicated strong similarities between the data sets. The Gene Symbol and SD log~2~FC columns are from the Wang, et al. paper, while the other columns are from the current study. Values shaded in red are up-regulated while values shaded in green are down-regulated.

Role of Sgk1 in orexin signaling {#sec017}
--------------------------------

One of the most highly orexin-responsive genes in GT1-7-OX~1~ cells, serum/glucocorticoid-regulated kinase 1 (*Sgk1*), is also highly up-regulated by SD. This transcript was of particular interest due to its roles in neuronal excitation and synaptic plasticity \[[@pone.0188082.ref083]--[@pone.0188082.ref086]\]. Sgk1 is expressed in all tissues of the body, including the brain, and regulates numerous ion channels, molecular transporters, and signaling proteins \[[@pone.0188082.ref087]--[@pone.0188082.ref091]\]. Transcription of *Sgk1* mRNA has been shown to be induced by several stimuli and, as it relates to orexin, by exposure to drugs of abuse \[[@pone.0188082.ref092],[@pone.0188082.ref093]\] or fasting conditions \[[@pone.0188082.ref094]--[@pone.0188082.ref096]\]. The *Sgk1* transcript was highly induced in response to OxA at both 3 and 8 hours (9-fold and 4-fold, respectively), with adj. p-values approaching zero. In order to examine the potential role of Sgk1 in orexin-regulated gene expression, an Sgk1 inhibitor, GSK-650394 \[[@pone.0188082.ref097]\], was added to GT1-7-OX~1~ cells prior to the addition of OxA. The effects of the Sgk1 inhibition on transcription of 89 of the most highly OX~1~-regulated genes were determined by qPCR ([S2 Fig](#pone.0188082.s002){ref-type="supplementary-material"}). From this set of genes, eleven showed reduced levels of induction when pretreated with GSK-650394 ([Fig 5](#pone.0188082.g005){ref-type="fig"}). These data argue that Sgk1 regulates these genes, possibly through phosphorylation of a transcription factor(s) that targets them. In an attempt to identify this putative factor(s), the PSCAN analysis was repeated with this set of genes ([S5 Table](#pone.0188082.s007){ref-type="supplementary-material"}). As seen in the earlier results, the Egr family of transcription factors was again identified. Interestingly, one of the other transcription factors identified, Sp1, is a known substrate of Sgk1 \[[@pone.0188082.ref098]\] and has been shown to regulate the transcription of *Ldlr* \[[@pone.0188082.ref099],[@pone.0188082.ref100]\], *Dok7* \[[@pone.0188082.ref101]\], *Rara* \[[@pone.0188082.ref102],[@pone.0188082.ref103]\], and *Cldn4* \[[@pone.0188082.ref104],[@pone.0188082.ref105]\].

![Inhibition of Sgk1 depresses the OxA-dependent induction of a small set of transcripts.\
GT1-7-OX~1~ cells were treated with an Sgk1 inhibitor, GSK-650394, prior to addition of OxA. Total RNA was purified from lysates and used for qPCR analysis. The genes displayed had their level of orexin-induced transcription inhibited by GSK-650394. Bars represent averages (n = 1, reads done in triplicate) while error bars represent SEM.](pone.0188082.g005){#pone.0188082.g005}

Discussion {#sec018}
==========

Because the orexin system has been shown to regulate behavior primarily via its actions in the central nervous system, studying orexin receptor signaling in a neuronal context is of particular interest. To that end, a recombinant model stably expressing OX~1~ was generated in GT1-7 cells, a mouse cell line derived from GnRH-expressing neurons of the hypothalamus. With this recombinant model established, RNA-Seq was used to identify a large set of genes regulated by OX~1~ signaling including several immediate early genes, transcription factors, kinases, and phosphatases. Results from qPCR validation experiments correlated well with the RNA-Seq data, affirming many of the transcriptional changes observed. In order to identify the primary transcriptional regulators or OX~1~ signaling, an *in silico* transcription factor binding site analysis was performed. While the occurrence of false positives is a legitimate concern when using these types of analyses, correlating these results with the gene expression data further supports roles for several of the transcription factors identified in the promoter analysis. Notably, these included related transcription factors such as *Egr1*, *Egr2*, and *Egr 3* as well as a number of Kruppel-like factors and the Myc transcription factor.

Of particular importance, though, is whether or not these data are physiologically relevant. To address this, the data were compared to those from similar studies focused on orexin-related behaviors, such as sleep and wakefulness. These comparisons demonstrated that OX~1~ signaling shows similarities with transcriptional profiles seen in *in vivo* SD microarray studies, with several genes being similarly regulated. This suggests that orexin signaling may be responsible for the SD-induced changes in expression of these genes. Indeed, SD has been shown to result in the activation of orexigenic neurons and increased OxA peptide levels in the brain, further supporting this hypothesis.

One of the genes highly regulated by both orexin signaling in GT1-7-OX~1~ cells and SD in the mouse brain is *Sgk1*, a kinase that is known to regulate a number of cellular proteins and is strongly associated with neuronal excitability, synaptic plasticity, and memory formation. As orexin also has strong associations with all of these processes, the role of Sgk1 in OX~1~ signaling seemed to be particularly interesting. These analogous roles imply that Sgk1 may be a crucial mediating factor in transducing the biological effects of orexin. A likely scenario is that, when induced by OX~1~ activation, Sgk1 phosphorylates cellular ion channels, altering the excitability of OX~1~-expressing neurons, thereby influencing associated behaviors.

In order to evaluate the downstream effects of Sgk1 on OX~1~ signaling, we analyzed the impact of Sgk1 inhibition on the orexin-dependent differential regulation of a subset of genes by qPCR. Inhibition of Sgk1 resulted in diminished induction of a small set of genes that included *Gja3*, *Ldlr*, *Dok7*, *Rara*, *Kcnk3*, and *Cldn4*, amongst others ([Fig 5](#pone.0188082.g005){ref-type="fig"}). Promoter analysis identified several putative transcription factors that could regulate these genes. Of these, Sp1 seems to be the most interesting, as it is known to be phosphorylated by Sgk1 and regulates transcription of many of the genes whose OX~1~-dependent transcription was impaired by Sgk1 inhibition, although the role of Sp1 was not empirically addressed in this study.

In summary, the orexin system sits at the crossroads of a diverse set of related behaviors including sleep, memory, synaptic plasticity, and addiction. To give insight into the molecular mechanisms influencing the role of orexin in regulating these behaviors, a neuronal, recombinant cell line was utilized to identify a set of candidate genes involved in OX~1~ signaling. Corroborating evidence in the literature strongly supports the physiological relevance of this data set, as several of the genes regulated by OX~1~ in the model cell line are similarly regulated by SD, *in vivo*. While this study brought focus to the role of Sgk1 in OX~1~ signaling, the data set is rich with other candidate genes whose capacity in OX~1~ signaling commands further study. Some examples include *Homer1*, *Arc*, *Nr4a1*, and *Ldlr*, each of which were heavily induced by OX~1~ signaling and have been associated with numerous orexin-related behaviors \[[@pone.0188082.ref073],[@pone.0188082.ref093],[@pone.0188082.ref106]--[@pone.0188082.ref110]\].
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###### Exploratory analysis.

A principle component analysis plot (A) and hierarchal clustering dendrogram (B) each show clear separation between treatment groups and strong clustering of samples within a condition.

(TIF)

###### 

Click here for additional data file.

###### Effects of Sgk1 inhibition on OX~1~-regulated transcription.

GT1-7-OX~1~ cells were treated OxA or with an Sgk1 inhibitor, GSK-650394, prior to the addition of OxA. A set of 89 OX~1~-regulated transcripts was assayed via qPCR. Data were analyzed by the 2^-ΔΔC^~T~ method using *B2m* as the endogenous control and are represented as fold-change over control samples (n = 1, reads done in triplicate).

(TIF)

###### 

Click here for additional data file.

###### List of TaqMan probes used in this work.

For each probe, the Applied Biosystems catalog number is given.

(XLSX)

###### 

Click here for additional data file.

###### Gene ID conversions.

The complete list of genes that were regulated 2-fold or greater, at 3h or 8h, by OxA in GT1-7-OX~1~ cells were entered into the DAVID Gene ID Conversion Tool to generate RefSeq mRNA IDs (See [Methods](#sec002){ref-type="sec"}). The RefSeq mRNA ID's were then entered into PSCAN for promoter analysis.

(XLSX)

###### 

Click here for additional data file.

###### List of primer pairs used for the Sgk1 inhibition qPCRs.

The complete set of 96 primer pairs includes 89 of the most highly OX~1~-regulated genes plus 7 housekeeping genes (*Actb*, *B2m*, *Gusb*, *Polr2a*, *Ppia*, *Rplp0*, and *Tbp*).

(CSV)

###### 

Click here for additional data file.

###### OX~1~-regulated genes.

A list of genes that were differentially regulated by OX~1~ signaling in both HEK293 and GT1-7 cells. The HEK293 Fold Up and Fold Down columns are from the Sikder, et. al paper while the remaining data are from this study.

(XLSX)

###### 

Click here for additional data file.

###### Partial PSCAN results for the putative Sgk1-regulated genes.

A PSCAN promoter analysis was performed using the eleven genes whose orexin-dependent induction was reduced by pre-incubation with the Sgk1 inhibitor.

(XLSX)

###### 

Click here for additional data file.
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